ANUH PHARMA LTD.
Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, Mumbai - 400018 INDIA.
Tel. : +91-22-6622 7575 • **Fax :** +91-22-6622 7600 / 7500
Email : anuh@sk1932.com • **CIN :** L24230MH1960PLC011586
Web: www.anuhpharma.com

Date: 30th October, 2026

To,
The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001
BSE Symbol: ANUHPHR
BSE Scrip Code: 506260

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex,
Bandra (East), Mumbai – 400051
NSE Symbol: ANUHPHR; Series: EQ

Subject: Outcome of Board Meeting dated, 30th October, 2026.

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform you that the Board of Directors of Anuh Pharma Limited (the Company) at its meeting held today, Friday, 30th October, 2026, has inter alia considered and approved the following:

1. The Un-Audited Financial Results along with Limited Review Report for the quarter and half year ended 30th September, 2026 (annexed as **Annexure – A**);

2. The requests received from the following Shareholder forming part of Promoter Group of the Company seeking withdrawn her application for reclassification and shall continue to remain a part of Promoter Group of the Company.

Sr No.	Name	Number of Equity shares held	% of shareholding
1.	Nina Vijay Shah	60,000	0.06
TOTAL		**60,000**	**0.06**

The Withdrawal request has been annexed as **Annexure – B;**

The Meeting of the Board of Directors commenced at **01:00 p.m.** and concluded at **04:10 p.m.**

ANUH PHARMA LTD.
Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, Mumbai - 400018 INDIA.
Tel. : +91-22-6622 7575 • **Fax :** +91-22-6622 7600 / 7500
Email : anuh@sk1932.com • **CIN :** L24230MH1960PLC011586
Web: www.anuhpharma.com

Kindly take the above on your records.

Thanking you,

Yours faithfully,

FOR ANUH PHARMA LIMITED

MANAN JAYESH VADHAN
Digitally signed by MANAN JAYESH VADHAN
Date: 2026.10.30 16:28:29 +05'30'

MANAN VADHAN
COMPANY SECRETARY & COMPLIANCE OFFICER
Encl: a/a

Annexure - A

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586
Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018
Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2026

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended 30/09/2026	3 months ended 30/06/2026	3 months ended 30/09/2025	6 months ended 30/09/2026	6 months ended 30/09/2025	12 months ended 31/03/2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
I	Revenue from operations	18,524.14	19,381.04	18,588.27	37,905.18	37,236.21	77,165.74
II	Other income	60.84	307.67	97.85	368.51	436.69	435.56
III	**Total Revenue (I + II)**	**18,584.98**	**19,688.71**	**18,686.12**	**38,273.69**	**37,672.90**	**77,601.30**
IV	Expenses:						
	Cost of materials consumed	14,182.71	15,996.42	13,151.03	30,179.13	25,541.53	51,044.32
	Purchases of Stock-in-Trade	48.02	414.33	1,839.16	462.35	4,488.80	7,919.67
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(453.59)	(1,579.88)	(536.84)	(2,033.47)	(314.58)	1,002.09
	Employee benefits expense	745.78	735.16	674.55	1,480.94	1,304.34	2,630.33
	Finance costs	5.18	0.35	7.56	5.53	28.69	47.23
	Depreciation and amortization expense	245.18	243.28	286.18	488.46	537.68	1,138.22
	Other expenses	2,306.93	2,186.24	2,272.42	4,493.17	3,999.07	8,397.30
	Total expenses (IV)	**17,080.21**	**17,995.90**	**17,694.06**	**35,076.11**	**35,585.53**	**72,179.16**
V	**Profit / (Loss) before exceptional and items and tax (III - IV)**	**1,504.77**	**1,692.81**	**992.06**	**3,197.58**	**2,087.37**	**5,422.14**
VI	Exceptional items	-	-	-	-	-	-
VII	**Profit / (Loss) before tax (V - VI)**	**1,504.77**	**1,692.81**	**992.06**	**3,197.58**	**2,087.37**	**5,422.14**
VIII	**Tax expenses:**						
	(1) Current tax	393.40	413.20	280.00	806.60	529.00	1,518.10
	(2) Deferred tax	(9.94)	137.12	(49.19)	127.18	(33.00)	(184.39)
	(3) Income tax of earlier years		-	-	-	-	(16.18)
	Total Tax expenses (VIII)	**383.46**	**550.32**	**230.81**	**933.78**	**496.00**	**1,317.53**
IX	**Profit/(Loss) after Tax (VII-VIII)**	**1,121.31**	**1,142.49**	**761.25**	**2,263.80**	**1,591.37**	**4,104.61**
X	**Other Comprehensive Income**						
	(i) Items that will not be reclassified to profit or loss	17.38	(4.40)	11.19	12.98	3.08	24.73
	(ii) Income Tax relating to the items that will not be reclassified to profit or loss	(4.38)	1.11	(2.82)	(3.27)	(0.78)	(6.22)
	(ii) Items that will be reclassified to profit or loss	-	-	-	-		-
	Total Other Comprehensive Income (net of Tax) (X) (net of Tax)	**13.00**	**(3.29)**	**8.37**	**9.71**	**2.30**	**18.51**
XI	**Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)**	**1,134.31**	**1,139.20**	**769.62**	**2,273.51**	**1,593.67**	**4,123.12**
	Paid up Equity Share Capital (Face value Rs. 5/- each) (Refer note no. 4)	**5,011.20**	**5,011.20**	**5,011.20**	**5,011.20**	**5,011.20**	**5,011.20**
	Other Equity (excluding revaluation reserves)		-	-	-	-	**30,211.04**
XII	**Earnings per equity share (For respective periods) (In Rs.) (Refer note no. 4)**						
	(1) Basic	1.12	1.14	0.76	2.26	1.59	4.10
	(2) Diluted	1.12	1.14	0.76	2.26	1.59	4.10
	See accompanying notes to the financial results						

ANUH PHARMA LTD. MUMBAI

STATEMENT OF ASSETS AND LIABILITIES

(Rs. in Lakhs)

	PARTICULARS	As at 30th September, 2026 Unaudited	As at 31st March, 2026 Audited
I	**ASSETS**		
1	**Non-current Assets**		
	(a) Property,Plant and equipment	4,472.49	4,799.41
	(b) Capital work-in-progress	24.97	-
	(c) Intangible Assets	43.57	52.89
	(d) Right of use assets	797.28	809.77
		5,338.31	5,662.07
	(e) Financial Assets		
	(i) Investments	2,506.52	3,960.07
	(ii) Loans and Advances	-	9.00
	(ii) Other Financial Assets	598.53	583.92
	(f) Deferred Tax Assets (Net)	255.76	386.20
	(g) Other Non Current Assets	28.19	5.78
	Total Non-Current Assets	8,727.31	10,607.04
2	**Current Assets**		
	(a) Inventories	17,245.36	14,775.50
	(b) Financial Assets		
	(i) Investments	8,778.46	4,484.16
	(ii) Trade receivables	18,978.01	23,863.28
	(iii) Cash and cash equivalents	939.93	805.97
	(iv) Other Bank balances	44.89	24.18
	(v) Loans and Advances	106.09	82.64
	(vi) Other financial assets	53.50	94.11
	(c) Other current assets	492.49	999.91
	Total Current Assets	46,638.73	45,129.75
	TOTAL ASSETS	55,366.04	55,736.79
II	**EQUITY AND LIABILITIES**		
	EQUITY		
	(i) Equity Share Capital	5,011.20	5,011.20
	(ii) Other Equity	30,981.18	30,211.04
	TOTAL EQUITY	35,992.38	35,222.24
	Liabilities		
1	**NON-CURRENT LIABLITIES**		
	(a) Financial Liaiblities		
	(i) Lease Liabilities	-	-
	(b) Provisions	184.57	214.22
	TOTAL NON-CURRENT LIABLITIES	184.57	214.22
2	**CURRENT LIABLITIES**		
	(a) Financial Liaiblities		
	(i) Borrowings	1,947.58	-
	(ii) Lease Liabilities	-	5.83
	(iii) Trade Payables:		
	Due to Micro and Small Enterprises	445.51	233.51
	Due to other than Micro and Small Enterprises	14,211.44	18,532.21
	(iv) Other financial liabilities	1,195.14	767.39
	(b) Other current liabilities	1,235.09	503.27
	(c) Provisions	31.37	26.50
	(d) Current Tax Liabilities(Net)	122.96	231.62
	TOTAL CURRENT LIABLITIES	19,189.09	20,300.33
	TOTAL EQUITY AND LIABILITIES	55,366.04	55,736.79

ANUH PHARMA LTD MUMBAI

ANUH PHARMA LIMITED

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th September, 2026

(Rs. in Lakhs)

	Particulars	Half Year Ended 30th September 2026		Half Year Ended 30th September 2025	
		Unaudited		Unaudited	
(A)	**CASH FLOW FROM OPERATING ACTIVITIES:**				
	NET PROFIT BEFORE TAX		3,197.58		2,087.37
	Adjustment for:				
	Depreciation and Amortization	488.46		537.68	
	Finance Costs	5.53		28.69	
	Interest Income	(25.45)		(34.63)	
	Property, Plant and Equipment W/Off / Discarded	0.82		-	
	Foreign Exchange (Gain)/Loss (Unrealised)	(256.77)		77.91	
	Market to Market (gain) / loss on investment (Net)	(135.75)		54.39	
	Market to Market loss / (gain) on Derivative (Net)	(11.42)		(0.86)	
	Sundry Credit Balance Written Back	(13.59)		(36.81)	
	Bad Debts Written Off	9.03		-	
	Fair Valuation on Unquoted Equity Share	88.35		-	
	Dividend Income	(3.17)		(2.82)	
	(Profit)/Loss on Sale of Property,Plant and Equipment (Net)	-		(8.38)	
	(Profit)/Loss on Sale of Investment (Net)	(202.95)		(390.86)	
			(56.91)		224.31
	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES		3,140.67		2,311.68
	Adjustment for:				
	Trade and Other Receivables	4,717.81		(1,659.80)	
	Inventories	(2,469.86)		(4,372.95)	
	Other Financial Assets	(35.33)		990.57	
	Loans and Advances	(14.46)		(5.15)	
	Other Current Assets	505.54		193.41	
	Trade Payables	(3,613.08)		409.28	
	Other Financial Liabilities	402.86		464.33	
	Other current Liabilities	731.82		(236.96)	
			225.30		(4,217.27)
	CASH GENERATED FROM OPERATIONS		3,365.97		(1,905.59)
	Direct Taxes paid (Net)	(697.74)	(697.74)	(774.37)	(774.37)
	NET CASH FROM OPERATIONS		2,668.23		(2,679.96)
(B)	**CASH FLOW FROM INVESTING ACTIVITIES:**				
	Sale of Investments	1,454.34		4,923.89	
	Purchase of Investments	(4,295.08)		(1,020.51)	
	Purchase of Property,Plant and Equipment and Capital Work in Progress	(189.81)		(437.00)	
	Sale of Property,Plant and Equipment	0.71		8.50	
	Interest Income	44.15		30.12	
	Dividend Income	3.17		2.82	
	NET CASH GENERATED/(USED IN) INVESTING ACTIVITIES		(2,982.52)		3,507.82
(C)	**CASH FLOW FROM FINANCING ACTIVITIES:**				
	Total Proceeds from Borrowings (net of repayments):				
	Secured Loans/Short Term Borrowings	1,947.58		(1,049.81)	
	Payment of Lease Liabilities	(5.90)		(8.85)	
	Finance Costs	(10.78)		(31.19)	
	Dividend paid (Including Tax thereon)	(1,482.65)		(1,499.73)	
	NET CASH (USED IN) FROM FINANCING ACTIVITIES		448.25		(2,589.58)
	NET INCREASE IN CASH AND CASH EQUIVALENTS (A + B + C)		133.96		(1,761.72)
	CASH AND CASH EQUIVALENT AS AT THE BEGINNING OF THE PERIOD		805.97		1,955.74
	CASH AND CASH EQUIVALENT AS AT THE END OF THE PERIOD		939.93		194.02

ANUH PHARMA LTD. MUMBAI

Notes:-

1. These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act 2013 ('the Act) read with the Companies (Indian Accounting Standards) Rules 2015, as amended from time to time, and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended).

2. These unaudited financial results for the quarter and half year ended September 30, 2026 were reviewed by the Audit Committee and approved by the Board of Directors at its respective meeting held on 30th October, 2026 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and have been subjected to limited review by the Statutory Auditors of the Company.

3. Other Financial indicators

(Rs. in Lakhs)

Particulars	3 months ended 30/09/2026	3 months ended 30/06/2026	3 months ended 30/09/2025	6 months ended 30/09/2026	6 months ended 30/09/2025	12 months ended 31/03/2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
EBITDA	1,755.13	1,936.44	1,285.80	3,691.57	2,653.74	6,607.59
% of EBITDA Margin	9.47	9.99	6.92	9.74	7.13	8.56
EBITDA (Adjusted to FOREX Gain / Loss and Other Income)	1,873.67	1,814.45	1,709.36	3,688.11	2,872.98	6,784.24
% of Adjusted EBITDA Margin	10.11	9.36	9.20	9.73	7.72	8.79

4. During the quarter ended September 30, 2025 the shareholders of the company have approved, through the postal ballot, the issuance of the bonus shares, in the proportion of 1:1 i.e. 1(one) bonus equity share of Rs 5 each for every 1(one) fully paid up equity share held on as on the record date. Accordingly, the company has allotted 5,01,12,000 as a bonus shares on 16th July, 2025 by utilization of General reserves. All the shares and per share information in the financial results reflect the effect of the bonus share issuance.

5. The Company does not have any subsidiary/associate/joint ventures as on 30th September 2026.

6. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

7. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Ltd.



Ritesh Shah
Joint Managing Director
(DIN: 02496729)

Place : Mumbai
Date : 30th October, 2026

JAYANTILAL THAKKAR & CO.
CHARTERED ACCOUNTANTS

111 (A) MAHATMA GANDHI ROAD,
FORT, MUMBAI - 400 023.
Telephones : (91-22) 2265 8800
(91-22) 2265 8900
E-Mails : jtco23@jtco.co.in
office@jtco.co.in
Website : www.jtco.co.in

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

TO THE BOARD OF DIRECTORS
Anuh Pharma Limited

1. We have reviewed the accompanying statement of unaudited financial results of Anuh Pharma Limited (the "Company") for the quarter ended 30th September,2026 and year to date from 1st April 2026 to 30th September 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For JAYANTILAL THAKKAR & CO.
CHARTERED ACCOUNTANTS
(FIRM REG. NO. 104133W)

JAYANTILAL THAKKAR & CO. CHARTERED ACCOUNTANTS FRN 104133W 111-A, M. G. RD., MUMBAI-23.

D. J. Thakkar

DILIP J. THAKKAR
PARTNER
MEMBERSHIP NO. 005369
UDIN: 26005369TCEJUV6463

PLACE: Mumbai
DATE: 30th October, 2026

Annexure - B

NINA VIJAY SHAH

Address: A 3807, Indiabulls, G K Marg, Worli, Mumbai – 400013, Maharashtra, India.
Email: nishit@sk1932.com; **Contact No.:** 9819603288

Date: 29th October, 2026

To,
The Deputy General Manager,
Listing Compliance Monitoring Cell,
24th Floor, P.J. Towers,
Dalal Street, Mumbai -400001

To,
Manager - Listing Compliance
National Stock Exchange of India Limited
'Exchange Plaza'. C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400051

CC: Anuh Pharma Limited

Subject: Withdrawal of Request for Reclassification under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Reference: Re-classification under Regulation 31A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") from Promoter Group category to public category of **Anuh Pharma Limited** (the "Company")

Dear Sir/Madam,

I, **Nina Vijay Shah**, a member of the Promoter Group of **Anuh Pharma Limited** ("Company"), refer to my request for reclassification from the **'Promoter' category to the 'Public' category** in terms of Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pursuant to which the Company had submitted an application to National Stock Exchange of India Limited and BSE Limited ("Exchange") seeking my reclassification.

Upon due consideration, I have decided to withdraw my request for reclassification. Accordingly, I hereby withdraw, with immediate effect, my request for reclassification made under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

I therefore request the Exchange to take this communication on record and treat the application submitted by the Company for my reclassification as **withdrawn**.

This withdrawal is made voluntarily and of my own free will, and I confirm that I shall continue to remain classified as a member of the Promoter Group of the Company unless otherwise permitted in accordance with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws.

I request you to kindly acknowledge receipt of this letter and take the necessary action in the matter.

NINA VIJAY SHAH

Address: A 3807, Indiabulls, G K Marg, Worli, Mumbai – 400013, Maharashtra, India.
Email: nishit@sk1932.com; **Contact No.:** 9819603288

Thanking you,
Yours faithfully,

Nina V. Shah

Nina Vijay Shah
Promoter Group Member
Anuh Pharma Limited

Email id: nishit@sk1932.com
Contact No.: 9819603288